BioSpace News Archive

argenx announced that it will host a conference call and audio webcast on Thursday, March 2, 2023 at 2:30 pm CET to discuss its full year 2022 financial results and provide a fourth quarter business update.

2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA nephropathy and a medication with the potential to be disease modifying based on the early stabilization of eGFR in patients at risk of rapid disease progression.

ONWARD Medical N.V., the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, announced it has been granted Breakthrough Device Designation status from the U.S. Food and Drug Administration for the use of its ARC-EX platform for bladder control, alleviation of spasticity, and blood pressure regulation in people with SCI.

Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2022.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full-year 2022 financial results and highlight recent corporate developments.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023 before the open of the U.S. financial markets.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported business highlights and financial results for the year ended December 31, 2022.

Option Care Health, Inc., the nation’s largest independent provider of home and alternate site infusion services, announced financial results for the fourth quarter and full year ended December 31, 2022.

Clearside Biomedical, Inc. announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets.